Literature DB >> 7543605

Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios.

J E Oesterling1, S J Jacobsen, G G Klee, K Pettersson, T Piironen, P A Abrahamsson, U H Stenman, B Dowell, T Lövgren, H Lilja.   

Abstract

PURPOSE: Prostate specific antigen (PSA) exists in the serum in several molecular forms that can be measured by immunodetectable assays: free PSA, PSA complexed to alpha 1-antichymotrypsin (complexed PSA) and total PSA, which represents the sum of the free and complexed forms. We determined the normal distribution of values and established the appropriate reference ranges for these 3 molecular forms of PSA and their ratios (free-to-total, complexed-to-total and free-to-complexed PSA). Knowing the amount and ratio of these molecular forms appears to be useful in enhancing the ability of PSA to distinguish potentially curable prostate cancer from benign prostatic hyperplasia and in decreasing the number of unnecessary prostate biopsies.
MATERIALS AND METHODS: A total of 422 healthy men 40 to 79 years old was randomly chosen from the male population of Olmsted County, Minnesota and underwent a detailed clinical examination that included digital rectal examination, serum PSA determination and transrectal ultrasound to exclude the presence of prostate cancer. Using newly developed, monoclonal-monoclonal immunofluorometric assays for each molecular form, the free, complexed and total PSA, and the ratios of these 3 forms were determined for each study participant.
RESULTS: All 3 molecular forms correlated directly with patient age (r = 0.45, r = 0.43 and r = 0.45, respectively). Using the 95th percentile, the recommended age-specific reference ranges for the free, complexed and total PSA forms, respectively, are 0.5, 1.0 and 2.0 ng./ml. for men 40 to 49 years old; 0.7, 1.5 and 3.0 ng./ml. for men 50 to 59 years old; 1.0, 2.0 and 4.0 ng./ml. for men 60 to 69 years old, and 1.2, 3.0 and 5.5 ng./ml. for men 70 to 79 years old. With regard to each of the ratios (free-to-total, complexed-to-total and free-to-complexed PSA) none correlated with patient age. As a result, the appropriate upper limit of normal (95th percentile) for all 3 ratios is constant for men of all ages. These reference ranges are greater than 0.15 for free-to-total PSA ratio, less than 0.70 for complexed-to-total PSA ratio and greater than 0.25 for free-to-complexed PSA ratio. The free-to-total PSA ratio will have its greatest value for men with a serum PSA value between 2 and 10 ng./ml.
CONCLUSIONS: The establishment of appropriate reference ranges for free, complexed and total PSA as well as the ratios will allow the practicing urologist to incorporate these new parameters into the diagnostic evaluation of men at risk for early, potentially curable prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7543605     DOI: 10.1016/s0022-5347(01)66984-2

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  28 in total

1.  Prostate cancer outcomes and delays in care.

Authors:  Michael E O'Callaghan; Zumin Shi; Tina Kopsaftis; Kim Moretti
Journal:  Int Urol Nephrol       Date:  2017-01-12       Impact factor: 2.370

2.  Modern Tumor Marker Discovery in Urology: Surface Enhanced Laser Desorption and Ionization (SELDI).

Authors:  Matthew B Gretzer; Alan W Partin; Daniel W Chan; Robert W Veltri
Journal:  Rev Urol       Date:  2003

3.  Macroscopic examination of prostatic specimens.

Authors:  C E Fuller
Journal:  J Clin Pathol       Date:  1996-07       Impact factor: 3.411

4.  Latest tests for prostatic neoplasia.

Authors:  W J Marshall
Journal:  J Clin Pathol       Date:  1998-05       Impact factor: 3.411

Review 5.  Stage T1c prostate cancer: defining the appropriate staging evaluation and the role for pelvic lymphadenectomy.

Authors:  M C Beduschi; R Beduschi; J E Oesterling
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

6.  The clinical value of the ratio of free prostate specific antigen to total prostate specific antigen.

Authors:  I Dalva; H Akan; O Yildiz; C Telli; N Bingol
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

7.  Determination and analysis of antigenic epitopes of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) using synthetic peptides and computer modeling.

Authors:  T Piironen; B O Villoutreix; C Becker; K Hollingsworth; M Vihinen; D Bridon; X Qiu; J Rapp; B Dowell; T Lövgren; K Pettersson; H Lilja
Journal:  Protein Sci       Date:  1998-02       Impact factor: 6.725

8.  Spectrophotometric photodynamic diagnosis of prostate cancer cells excreted in voided urine using 5-aminolevulinic acid.

Authors:  Yasushi Nakai; Makito Miyake; Satoshi Anai; Shunta Hori; Yoshihiro Tatsumi; Yosuke Morizawa; Sayuri Onisi; Nobumichi Tanaka; Kiyohide Fujimoto
Journal:  Lasers Med Sci       Date:  2018-05-04       Impact factor: 3.161

Review 9.  Prostate cancer, Incidence, management and outcomes.

Authors:  E J Small
Journal:  Drugs Aging       Date:  1998-07       Impact factor: 3.923

10.  Patients treated with radical prostatectomy with positive digital rectal examination findings in the intermediate-risk group are prone to PSA recurrence.

Authors:  Nobuki Furubayashi; Takahito Negishi; Shintaro Ura; Jun Mutaguchi; Kenichi Taguchi; Mototsugu Shimokawa; Motonobu Nakamura
Journal:  Oncol Lett       Date:  2016-04-20       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.